Emergent BioSolutions (EBS) Cost of Revenue (2011 - 2026)

Emergent BioSolutions' Cost of Revenue history runs 16 years deep, the most recent figure standing at $72.0 million for Q1 2026.

• On a quarterly basis, Cost of Revenue fell 18.64% year-over-year to $72.0 million in Q1 2026; TTM through Mar 2026 was $309.7 million, a 18.31% decrease from a year earlier, with the FY2025 full-year figure at $326.2 million, down 52.12% from the prior year.
• Cost of Revenue fell to $72.0 million in Q1 2026 per EBS's latest filing, from $84.9 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $190.6 million in Q2 2023 and bottomed at $50.0 million in Q2 2024.
• The 5-year median for Cost of Revenue is $118.0 million (2024), against an average of $118.4 million.
• Across the five-year window, Cost of Revenue jumped 9194.44% in 2022 and slumped 73.77% in 2024, its largest moves.
• Year by year, Cost of Revenue stood at $167.3 million in 2022, then rose by 10.64% to $185.1 million in 2023, then sank by 36.25% to $118.0 million in 2024, then fell by 28.05% to $84.9 million in 2025, then declined by 15.19% to $72.0 million in 2026.
• Per Business Quant, the three latest EBS Cost of Revenue figures stand at $72.0 million (Q1 2026), $84.9 million (Q4 2025), and $85.9 million (Q3 2025).